Botulinum toxin type A
Botulinum toxin type A is the serotype behind many of the most visible botulinum toxin products. It appears across therapeutic neurology, rehabilitation, sweating disorders, selected pain-related treatment contexts, glandular uses, and aesthetic facial treatment. It is still a biologic category rather than a single medicine.
Product Ecosystem
Section titled “Product Ecosystem”Type A has the broadest product footprint in the current Botulinum Index graph. The important relationship is not just “which brands are type A,” but how product names connect to manufacturers, regional labels, formulation discussion, and comparison limits.
| Product node | Manufacturer / company context | Reading note |
|---|---|---|
| Botox | AbbVie / Allergan | A major reference brand across therapeutic and aesthetic discussions, with product-specific labels and unit language. |
| Dysport | Ipsen product context; Galderma aesthetic commercialization | Often compared with Botox because both are visible type A products, but their units are not interchangeable. |
| Xeomin | Merz Pharma | Often discussed through formulation and handling differences within the type A category. |
| Jeuveau | Daewoong Pharmaceutical manufacturing; Evolus commercialization | A Korea-origin type A product node with important U.S. aesthetic-market visibility. |
| Daxxify | Revance / Crown Laboratories | A U.S.-approved type A product with peptide-formulated product identity and aesthetic plus cervical dystonia label context. |
| Letybo | Hugel | A Korea-origin type A product with U.S. glabellar-line approval and broader market-specific naming context. |
Galderma also adds Relfydess, or relabotulinumtoxinA, as an international type A product and U.S. development node. Its approvals are market-specific, and FDA acceptance of its February 2026 BLA resubmission for review is not U.S. approval.
Those products can share a serotype while remaining distinct regulated medicines. Shared type A biology does not create a universal conversion ratio, a common approval profile, or a general ranking.
Mechanism Context
Section titled “Mechanism Context”Type A reduces acetylcholine release by acting on SNAP-25, a SNARE protein involved in signal release from the nerve ending. Acetylcholine is a chemical messenger used by cholinergic nerves to communicate with muscles and glands. When release is reduced in a selected target pattern, muscle contraction or glandular activity can temporarily decrease.
The broader sequence is covered in botulinum toxin mechanism of action. For comparison with type B, see botulinum toxin type A vs type B.
Label And Clinical Footprint
Section titled “Label And Clinical Footprint”Type A products have a broad clinical and aesthetic footprint, but that footprint is not a single shared approval profile. A product may have strong evidence for one use, a different label in another region, and common discussion elsewhere that does not equal approval.
This distinction is especially important in comparison content. “Type A” can identify a mechanism family, but it does not answer which indications are approved, which warnings apply, how units are defined, or whether a product is available in a particular market.
Unit And Comparison Limits
Section titled “Unit And Comparison Limits”Type A products use product-specific potency units. A larger headline unit number does not automatically mean a stronger, wider-spreading, longer-lasting, or safer treatment. Unit interpretation belongs inside product labeling, clinical evidence, anatomy, and treatment plan.
This issue shapes how readers should approach diffusion claims, immunogenicity discussion, and brand comparisons. Type A is a useful category, but product-specific evidence carries the interpretive weight.